The global Gabapentin market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030. The growth of the market is attributed to factors such as increasing prevalence of neuropathic pain and epilepsy, growing geriatric population, and rising awareness about the benefits of Gabapentin for treating various conditions.
The global Gabapentin market is segmented on the basis of type into capsule and tablet; on the basis of application into epilepsy, neuropathic pain, and restless legs syndrome; and on the basis of region into North America, Latin America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA). The North American region dominates in terms of revenue share in 2018 due to high prevalence rates for epilepsy in this region. However APAC is expected to grow at a higher CAGR during forecast period owing to increasing awareness about benefits associated with Gabapentin use for treating various conditions such as neuropathic pain or restless legs syndrome.
-It has been approved by the FDA for use in adults and children over 12 years old.
-The drug is also used to treat postherpetic neuralgia, which is a complication of shingles.
-In 2013, it was estimated that there were about 3 million people who had taken Gabapentin at some point in their lives.
Industry Growth Insights published a new data on “Gabapentin Market”. The research report is titled “Gabapentin Market research by Types (Capsule, Tablet), By Applications (Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others), By Players/Companies Pfizer, Assertio Therapeutics, TEVA, Mylan, Arbor Pharma, Novartis, Apotex, Sun Pharmaceutical, Aurobindo Pharma, Intas, Amneal, Marksans Pharma, Glenmark, Alkem, Jiangsu Enhua, Jiangsu Hengrui, Sailike”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Gabapentin Market Research Report
By Type
Capsule, Tablet
By Application
Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others
By Companies
Pfizer, Assertio Therapeutics, TEVA, Mylan, Arbor Pharma, Novartis, Apotex, Sun Pharmaceutical, Aurobindo Pharma, Intas, Amneal, Marksans Pharma, Glenmark, Alkem, Jiangsu Enhua, Jiangsu Hengrui, Sailike
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Gabapentin Market Report Segments:
The global Gabapentin market is segmented on the basis of:
Types
Capsule, Tablet
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Assertio Therapeutics
- TEVA
- Mylan
- Arbor Pharma
- Novartis
- Apotex
- Sun Pharmaceutical
- Aurobindo Pharma
- Intas
- Amneal
- Marksans Pharma
- Glenmark
- Alkem
- Jiangsu Enhua
- Jiangsu Hengrui
- Sailike
Highlights of The Gabapentin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsule
- Tablet
- By Application:
- Epilepsy
- Neuropathic Pain
- Restless Legs Syndrome
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gabapentin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gabapentin is a medication used to treat seizures and other conditions. It works by affecting the brain and nerves. Gabapentin is usually taken by mouth, but it can also be given as an injection into a muscle.
Some of the major players in the gabapentin market are Pfizer, Assertio Therapeutics, TEVA, Mylan, Arbor Pharma, Novartis, Apotex, Sun Pharmaceutical, Aurobindo Pharma, Intas, Amneal, Marksans Pharma, Glenmark, Alkem, Jiangsu Enhua, Jiangsu Hengrui, Sailike.
The gabapentin market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Gabapentin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Gabapentin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Gabapentin Market - Supply Chain
4.5. Global Gabapentin Market Forecast
4.5.1. Gabapentin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Gabapentin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Gabapentin Market Absolute $ Opportunity
5. Global Gabapentin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Gabapentin Market Size and Volume Forecast by Type
5.3.1. Capsule
5.3.2. Tablet
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Gabapentin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Gabapentin Market Size and Volume Forecast by Application
6.3.1. Epilepsy
6.3.2. Neuropathic Pain
6.3.3. Restless Legs Syndrome
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Gabapentin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Gabapentin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Gabapentin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Gabapentin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Gabapentin Demand Share Forecast, 2019-2026
9. North America Gabapentin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Gabapentin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Gabapentin Market Size and Volume Forecast by Application
9.4.1. Epilepsy
9.4.2. Neuropathic Pain
9.4.3. Restless Legs Syndrome
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Gabapentin Market Size and Volume Forecast by Type
9.7.1. Capsule
9.7.2. Tablet
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Gabapentin Demand Share Forecast, 2019-2026
10. Latin America Gabapentin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Gabapentin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Gabapentin Market Size and Volume Forecast by Application
10.4.1. Epilepsy
10.4.2. Neuropathic Pain
10.4.3. Restless Legs Syndrome
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Gabapentin Market Size and Volume Forecast by Type
10.7.1. Capsule
10.7.2. Tablet
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Gabapentin Demand Share Forecast, 2019-2026
11. Europe Gabapentin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Gabapentin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Gabapentin Market Size and Volume Forecast by Application
11.4.1. Epilepsy
11.4.2. Neuropathic Pain
11.4.3. Restless Legs Syndrome
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Gabapentin Market Size and Volume Forecast by Type
11.7.1. Capsule
11.7.2. Tablet
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Gabapentin Demand Share, 2019-2026
12. Asia Pacific Gabapentin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Gabapentin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Gabapentin Market Size and Volume Forecast by Application
12.4.1. Epilepsy
12.4.2. Neuropathic Pain
12.4.3. Restless Legs Syndrome
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Gabapentin Market Size and Volume Forecast by Type
12.7.1. Capsule
12.7.2. Tablet
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Gabapentin Demand Share, 2019-2026
13. Middle East & Africa Gabapentin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Gabapentin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Gabapentin Market Size and Volume Forecast by Application
13.4.1. Epilepsy
13.4.2. Neuropathic Pain
13.4.3. Restless Legs Syndrome
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Gabapentin Market Size and Volume Forecast by Type
13.7.1. Capsule
13.7.2. Tablet
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Gabapentin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Gabapentin Market: Market Share Analysis
14.2. Gabapentin Distributors and Customers
14.3. Gabapentin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Assertio Therapeutics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. TEVA
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Mylan
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Arbor Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Apotex
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sun Pharmaceutical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Aurobindo Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Intas
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Amneal
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Marksans Pharma
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Glenmark
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Alkem
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Jiangsu Enhua
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Jiangsu Hengrui
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Sailike
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
